Answers are grounded in this paper and cite their sources.
Background Epithelial-derived cytokines, particularly thymic stromal lymphopoietin (TSLP) and interleukin-33 (IL-33), are key regulators of airway inflammation and promising therapeutic targets for severe asthma. However, evidence regarding the efficacy and safety of biologics targeting these pathways remains inconsistent. We conducted a systematic review and meta-analysis to evaluate their efficacy and safety in severe asthma. Methods PubMed/MEDLINE, Google Scholar, ScienceDirect, the Cochrane Library, and ClinicalTrials.gov were systematically searched from database inception through June 2026. Randomized controlled trials evaluating anti-TSLP or anti-IL-33/ST2 biologics in adolescents or adults with severe or uncontrolled asthma were included. The primary outcome was the risk of experiencing at least one severe asthma exacerbation during the treatment period. Secondary outcomes included annualized asthma exacerbation rate (AAER), pre-bronchodilator forced expiratory volume in one second (FEV₁), Asthma Control Questionnaire (ACQ), Asthma Quality of Life Questionnaire (AQLQ), adverse events (AEs), and serious adverse events (SAEs). Random-effects meta-analysis was performed using Review Manager 5.4. Results Nine randomized controlled trials involving 3,603 participants were included. Epithelial cytokine-targeted biologics significantly reduced the risk of experiencing at least one severe asthma exacerbation compared with placebo or control (RR = 0.71, 95% CI: 0.60–0.83; P < 0.0001). Significant improvements were observed in AAER, pre-bronchodilator FEV₁ (MD = 0.14 L, 95% CI: 0.08–0.20; P < 0.0001), ACQ (MD = − 0.31, 95% CI: −0.38 to − 0.25; P < 0.00001), and AQLQ (MD = 0.33, 95% CI: 0.25–0.41; P < 0.00001). Eosinophil-based subgroup analyses demonstrated significant reductions in AAER in both eosinophil categories, whereas FEV₁ significantly improved only among patients with levels ≥ 300 cells/µL. TSLP-targeting biologics significantly reduced severe asthma exacerbation risk, whereas the reduction with IL-33/ST2-targeting biologics was not statistically significant. No significant increase in AEs was observed (RR = 0.96, 95% CI: 0.90–1.02; P = 0.06), while SAEs were significantly reduced (RR = 0.76, 95% CI: 0.62–0.95; P = 0.02). Conclusions Biologics targeting epithelial cytokines significantly reduce severe asthma exacerbations and AAER, improve lung function, asthma control and quality of life, and demonstrate a favorable safety profile in severe asthma. These findings support epithelial cytokine-targeted biologics as an effective and generally well-tolerated therapeutic strategy, although differences between individual biologics and targeted pathways should be considered. The protocol was registered with PROSPERO (CRD420261446519).
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: